The Centers for Disease Control (CDC) advisory panel have recommended that people should not get the Johnson & Johnson (J&J) COVID-19 vaccine if the Moderna and Pfizer-BioNTech shots are available. The Advisory Committee on Immunization Practices announced its recommendations after the Food and Drug Administration (FDA) said the J&J vaccine has been linked to a rare but potentially deadly blood clot.
The CDC panel endorsed the FDA’s update after hearing new data showed individuals who recently received a J&J vaccine were common among those that developed a rare blood clotting syndrome. There have been 54 cases logged in the US of thrombosis with thrombocytopenia syndrome (TTS) in the United States. These cases only developed after the J&J vaccine became available.
In addition, nine individuals have passed away; two men and seven women, according to the CDC’s data. Dr. Isaac See from the CDC stated the rates are higher than previously estimated among both women and men. He added there have only been a few cases seen for every million people vaccinated by age group. However, these cases are higher than what vaccine advisers first believed.
Dr. See added that they have “been struck on reviewing these cases by how rapidly a patient deteriorates [leading] to death.” On average, individuals began showing symptoms within nine days to two weeks of receiving the vaccine.
During a press conference See stated, “The US TTS case reporting rate following Janssen Covid-19 vaccination is higher than what was previously presented to ACIP and the case reporting rate for men 40-49 years and for women 50-64 is similar to that for women 18-29 years.”
Of the 54 cases, 39 of them were reported before the CDC and the FDA paused the administration of the COVID vaccine to investigate the situation. Since they paused the administration in April, the CDC has learned of additional cases.
The information the CDC gathered states the highest rates of TTS among women are 10 per million vaccinations given in women ages 30 to 39. The data also shows that rates of TTS among women are 9 per million in women ages 40 to 49.
Dr. Sara Oliver from the CDC stated that women are at a higher risk of developing TTS than men. She added, “The VE (vaccine effectiveness) is lower for the Janssen vaccine compared to mRNA vaccines.”
People should weigh the pros and cons when they are deciding which vaccine they should receive.
Written by Sheena Robertson
CNN: CDC vaccine advisers vote to recommend Pfizer, Moderna vaccines over J&J’s; by Maggie Fox
Inset Image by Cotton Puryear Courtesy of The National Guard’s Flickr Page – Creative Commons License
Top and Featured Image Courtesy of Jimmy Baikovicius’s Flickr Page – Creative Commons License